Treats complicated urinary tract infections (cUTI) including acute pyelonephritis caused…. Sold as Contepo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Fosfomycin Disodium (sold as Contepo), first approved Oct 22, 2025, with 0 new uses approved and 1 published complete response letter.
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial InfectionsGram Negative Infections, Sepsis and Septic Shock · Angela HUTTNER | Phase 3 | Recruiting | Jul 14, 2025 |
| Letter | Product | Now |
|---|---|---|
| Dec 11, 2024 | NDA 212271Product Quality/ Facility Inspections | Unapproved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA